Glucosamine is widely taken to relieve joint pain, but new research suggests it may worsen memory problems in people with Alzheimer’s disease by fueling abnormal sugar modifications in the brain. The findings raise questions about how a supplement considered relatively safe might behave differently in an already vulnerable brain.
For millions of older adults, taking glucosamine is part of a familiar daily routine. The supplement, often marketed for joint health and relief from osteoarthritis, has long been regarded as relatively safe, even as its effectiveness for joint pain remains debated. But a study published in Nature Metabolism in June 2026 raises an unexpected concern: glucosamine use was associated with faster progression of cognitive impairment and poorer survival among people with Alzheimer’s disease and related dementias.
Researchers at the University of Florida discovered that the brains of people with Alzheimer’s disease contain unusually high levels of complex sugar molecules attached to proteins. These modifications, normally essential for healthy cellular function, appear to become excessive in regions responsible for memory and cognition. The researchers also found that giving glucosamine to mice with Alzheimer’s-like disease intensified these abnormalities and worsened memory performance, whereas reducing the excessive sugar modifications improved memory.
An accompanying analysis of more than 66,000 patient records found that people with mild cognitive impairment who had documented glucosamine use were approximately 25 percent more likely to progress to dementia than matched nonusers. Among patients with established Alzheimer’s disease or related dementias, glucosamine use was associated with a 25 percent higher mortality risk.
Although these findings do not establish that glucosamine causes cognitive decline in humans, they suggest a possible connection between a commonly used supplement and a previously underappreciated metabolic disturbance in Alzheimer’s disease.
How a Joint Supplement Could Affect the Brain
Glucosamine is a naturally occurring compound involved in the production of substances that support cartilage and other connective tissues. Its popularity as a supplement stems from the belief that providing additional glucosamine might help maintain joint structure or reduce discomfort associated with osteoarthritis.
But glucosamine does not act exclusively in joints. Once absorbed, it can enter metabolic pathways used throughout the body, including pathways involved in producing complex sugar molecules called glycans. These structures attach to proteins through a process known as glycosylation.
Glycosylation is essential for life. It helps proteins acquire their proper shape, reach the correct cellular locations, and communicate with other molecules. In the brain, these sugar attachments are particularly important for receptors and channels that allow nerve cells to transmit information.
Problems may arise, however, when too many sugar molecules are attached to proteins or when the normal pattern of these modifications becomes disrupted.
The University of Florida researchers identified precisely such an imbalance in brain tissue from people with Alzheimer’s disease. Elevated levels of N-linked glycans, a major type of sugar attachment, were detected particularly in gray matter, which contains many of the neurons responsible for memory, reasoning, and information processing.
The accumulation became more pronounced in tissue with advanced Alzheimer’s-related pathology, suggesting that these changes may accompany disease progression.
This process, known as hyperglycosylation, offers a possible explanation for why glucosamine might affect an already diseased brain differently from a healthy one. By supplying additional material for glycan production, glucosamine could potentially intensify an abnormal metabolic pathway that is already overactive in Alzheimer’s disease.
Importantly, this is not the same as saying that eating sugar causes these abnormalities. Glycosylation is a regulated cellular process, and the study specifically examined how glucosamine and related metabolic pathways influence sugar attachments to proteins.
When Too Much Sugar Disrupts Brain Communication
For decades, Alzheimer’s research has focused primarily on two characteristic abnormalities: amyloid plaques that accumulate between nerve cells and tangled tau proteins that interfere with their internal structure. Yet these changes do not fully explain the severity of memory impairment experienced by every patient.
The new research suggests that abnormal glycosylation may represent another contributor to cognitive dysfunction.
Using advanced molecular imaging techniques, investigators examined donated human brain tissue alongside brain tissue from mice genetically modified to develop Alzheimer’s-related abnormalities. Excessive glycan accumulation was observed in regions involved in cognition, particularly the cortex and hippocampus.
The researchers then traced how glucose-derived molecules were processed in the brains of affected mice. They found that the elevated glycan levels resulted primarily from increased production of new sugar structures rather than a failure to remove old ones.
Further analysis suggested that many of the additional sugar attachments appeared on proteins already present on neuronal membranes. These proteins help regulate electrical activity and communication between nerve cells, processes that are essential for forming and retrieving memories.
A neuron depends on the precise functioning of thousands of proteins to receive, interpret, and transmit information. Excessive glycosylation could potentially alter how these proteins behave, interfering with neuronal communication even without producing additional visible structural damage.
This may help explain one of the study’s more intriguing observations: memory performance in affected mice improved when excessive glycosylation was reduced, even though amyloid plaques and tau-related abnormalities remained largely unchanged during the experiments.
The finding raises the possibility that some cognitive impairment in Alzheimer’s disease may result from disturbances in neuronal function that operate alongside, rather than solely through, amyloid and tau pathology.
Glucosamine Worsened Memory in Mice With Alzheimer’s-Like Disease
To explore whether the abnormal accumulation of glycans could influence memory, researchers tested two opposing approaches.
First, they reduced glycan production using experimental methods that interfered with enzymes responsible for manufacturing or attaching these sugar structures to proteins. Mice with Alzheimer’s-related abnormalities subsequently performed better on tests of social recognition memory, suggesting that some aspects of cognitive function had improved.
The researchers then investigated what would happen if additional glucosamine were supplied.
In mice genetically predisposed to Alzheimer’s-like disease, oral glucosamine supplementation produced widespread increases in brain glycans and substantially worsened memory performance. The animals became less able to recognize mice they had encountered previously, a behavioral measure used to evaluate recognition memory.
The contrast with healthy mice was striking. When glucosamine was given to animals without Alzheimer’s-related abnormalities, comparable increases in brain glycans or memory impairment were not observed.
These findings suggest that an already diseased brain may have difficulty maintaining normal glycan metabolism when additional glucosamine becomes available. In this experimental setting, the supplement appeared to amplify an existing metabolic disturbance rather than create the same disturbance in healthy animals.
However, the experiments were conducted in genetically modified mice, and social recognition tests do not reproduce the complexity of human memory loss. The findings provide biological evidence for a possible harmful effect in Alzheimer’s-like disease, but they cannot establish whether typical glucosamine doses produce the same consequences in patients.
What the Study Found in More Than 66,000 Patients
To investigate whether the experimental findings might have clinical relevance, researchers analyzed electronic health records from the University of Florida Health system.
The analysis included 41,884 people with mild cognitive impairment, a condition involving measurable changes in memory or thinking that do not yet substantially interfere with independent daily functioning, and 24,481 patients diagnosed with Alzheimer’s disease or related dementias.
Approximately 8 percent had documented glucosamine use.
Among patients with mild cognitive impairment, those with recorded glucosamine use had a 25 percent higher observed proportion progressing to dementia than matched nonusers. This was a relative difference between groups, not evidence that an additional 25 percent of all glucosamine users developed dementia.
Among individuals already diagnosed with Alzheimer’s disease or related dementias, glucosamine use was associated with a 25 percent increase in mortality risk. No statistically significant increase in mortality was observed among the patients with mild cognitive impairment.
The pattern suggests a possible relationship between glucosamine exposure and the severity of existing neurological disease. However, the results do not establish that glucosamine itself caused faster deterioration.
Because the analysis relied on existing medical records rather than a randomized clinical trial, people who used glucosamine may have differed from nonusers in ways not fully captured by the researchers. Joint disease, reduced mobility, frailty, other medications, supplement-taking habits, and differences in medical care could have influenced outcomes.
Moreover, medical records cannot always determine the amount of glucosamine actually consumed or whether patients continued taking it consistently. The researchers also could not directly measure glycan accumulation in the brains of the patients included in the record analysis.
The human findings therefore support further investigation of the proposed mechanism but do not prove that glucosamine accelerates Alzheimer’s disease.
Why Previous Research Has Told a Different Story
The possibility that glucosamine could worsen dementia is particularly intriguing because earlier studies have not consistently identified the supplement as a neurological risk.
A 2023 study published in BMC Medicine found an association between regular glucosamine use and a lower incidence of dementia. Another large prospective study, published in The Journals of Gerontology in 2024 and involving approximately 290,000 participants, found no statistically significant association between glucosamine supplementation and the subsequent development of dementia.
These findings are not necessarily incompatible with the new research. The earlier studies primarily examined people who did not have dementia at the beginning of follow-up, whereas the 2026 study focused on individuals already living with cognitive impairment or dementia.
It is possible that glucosamine has different effects depending on the metabolic condition of the brain, although this explanation remains hypothetical.
Additional uncertainty emerged from a July 2026 preprint examining data from the National Alzheimer’s Coordinating Center. Investigators found that the association between glucosamine records and dementia progression was not clearly distinguishable from patterns observed among people taking other supplements, including multivitamins and calcium or vitamin D. The analysis also did not confirm an increased adjusted mortality risk among glucosamine users with dementia.
Because this subsequent analysis has not undergone peer review, its conclusions remain preliminary. Nevertheless, it highlights how difficult it can be to separate the biological effects of a supplement from the health characteristics and behaviors of the people who take it.
The strongest conclusion at present is that glucosamine has been shown to worsen memory-related performance in experimental Alzheimer’s models, while its effect on dementia progression in humans remains uncertain.
Should People With Alzheimer’s Disease Stop Taking Glucosamine?
The new findings raise a practical question for patients and families, particularly because glucosamine is available without a prescription and is often used for years.
For someone already diagnosed with mild cognitive impairment or Alzheimer’s disease, the study provides a reason to reconsider whether continued glucosamine supplementation offers meaningful benefits.
There is an additional consideration: the supplement’s effectiveness for osteoarthritis remains controversial. The American College of Rheumatology and Arthritis Foundation guidelines recommend against glucosamine for hand, hip, and knee osteoarthritis because higher-quality evidence has generally failed to demonstrate clinically important benefits over placebo.
When the expected benefit of a supplement is uncertain, even an unconfirmed concern about potential harm deserves attention.
However, the new Alzheimer's findings do not justify a blanket conclusion that glucosamine is dangerous or that all patients should immediately discontinue it. The evidence does not establish a harmful dose in humans, nor does it show that stopping glucosamine improves memory or slows dementia.
For patients already experiencing cognitive difficulties, reviewing supplement use with a healthcare professional may be appropriate, especially when glucosamine provides little noticeable improvement in joint symptoms.
A New Clue to Alzheimer’s Disease Beyond Amyloid and Tau
Beyond the questions surrounding glucosamine, the research suggests a potentially important direction for understanding Alzheimer’s disease.
The brain depends not only on healthy neurons but also on carefully regulated biochemical processes that allow those neurons to communicate. Glycosylation is one of those processes. When its balance becomes disrupted, proteins that are structurally intact may no longer function as intended.
The observation that reducing excessive glycosylation improved memory-related behavior in mice without removing amyloid plaques suggests that metabolic abnormalities may contribute to cognitive decline through mechanisms partly independent of traditional Alzheimer’s pathology.
Whether such changes can be safely corrected in humans remains unknown. Glycosylation is essential to normal cellular function, so any future therapy would need to target the harmful imbalance without disrupting necessary protein modifications.
Clinical studies will also be required to determine whether glucosamine truly worsens outcomes in patients with existing cognitive impairment and whether particular doses, formulations, or disease stages carry different risks.
For now, the study offers a new perspective on how a familiar dietary supplement might interact with an already vulnerable brain. It also reinforces an important principle of medicine: a substance considered relatively safe for one condition or population may have different effects when the underlying biology changes.
In Alzheimer’s disease, that difference may eventually help explain why neuronal communication fails and whether some of that dysfunction can be prevented or reversed.
Reference
1. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer’s disease. Nat Metab. 2026;8(6):1410-1425. doi:10.1038/s42255-026-01538-4
2. Nakashima S, Sato K, Niimi Y, Satake W, Iwatsubo T. Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer’s disease. medRxiv. Preprint posted July 27, 2026. doi:10.64898/2026.07.23.26358748
3. Zheng J, Ni C, Zhang Y, et al. Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114. doi:10.1186/s12916-023-02816-8
4. Ai B, Chen L, Cai M, et al. No associations between glucosamine supplementation and dementia or Parkinson’s disease: findings from a large prospective cohort study. J Gerontol A Biol Sci Med Sci. 2024;79(2):glad123. doi:10.1093/gerona/glad123
5. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233. doi:10.1002/art.41142
